Recurrent duodenal ulcer haemorrhage: a pharmacoeconomic comparison of various management strategies.
BACKGROUND
Duodenal ulcer (DU) bleeding has a 7 - 13% mortality rate and bleeding often recurs. Prevention of recurrence is, therefore, an important goal. Eradication of Helicobacter pylori or maintenance treatment with a proton pump inhibitor (PPI) may reduce recurrent DU bleeding. Economic comparison of these options is sparse.


METHODS
After the control of index bleeding with endotherapy and drugs, three strategies were evaluated: empirical treatment for possible H. pylori infection followed by a PPI for 2 months; test for H. pylori, eradication if positive, maintenance PPI if negative; maintenance PPI alone. Probability and direct cost data were obtained from a Medline search and Indian hospitals, respectively. Cost-minimisation, cost-utility, one- and two-way sensitivity analyses and threshold values were evaluated.


RESULTS
Treatment of H. pylori, particularly empirical, was the preferred strategy and dominated maintenance treatment with PPI. The test-and-treat strategy was better than the empirical treatment strategy only when the probabilities of H. pylori eradication, ulcer healing following eradication and of frequency of H. pylori infection in bleeding DU were less than 58, 73 and 58%, respectively.


CONCLUSIONS
Eradication of H. pylori is preferred in preventing recurrent bleeding from DU.
Ghoshal
Uday Chand
UC
Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Raebareli Road, Lucknow 226014, India. ghoshal@sgpgi.ac.in
Aggarwal
Rakesh
R
Baba
Chalamalasetty Sreenivasa
CS
D002986:Clinical Trials as Topic; D003365:Costs and Cost Analysis; D004381:Duodenal Ulcer / Q000150:complications / Q000188:drug therapy / Q000191:economics*; D016481:Helicobacter Infections / Q000150:complications / Q000188:drug therapy / Q000191:economics / Q000382:microbiology; D016480:Helicobacter pylori; D006801:Humans; D018803:Models, Economic; D010438:Peptic Ulcer Hemorrhage / Q000188:drug therapy / Q000191:economics* / Q000209:etiology; D054328:Proton Pump Inhibitors; D017494:Proton Pumps / Q000191:economics / Q000627:therapeutic use; D011788:Quality of Life
D054328:Proton Pump Inhibitors; D017494:Proton Pumps